NewAmsterdam Pharma Company NV (NASDAQ:NAMS) price on current trading day, rose 4.62% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $15.86.
A look at the stock’s price movement, the close in the last trading session was $15.16, moving within a range at $14.28 and $16.64. The beta value (5-Year monthly) was -0.002. Turning to its 52-week performance, $27.29 and $14.06 were the 52-week high and 52-week low respectively. Overall, NAMS moved -30.68% over the past month.
NewAmsterdam Pharma Company NV’s market cap currently stands at around $1.74 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-25.
The average forecast suggests up to a 11.85% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 15.92M, representing a -63.32% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that NAMS is a Hold. On the other hand, the stock is on average a Hold as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
1 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 1 recommend NAMS as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
NAMS’s current price about -24.01% and -23.72% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 25.43, while 7-day volatility ratio is 13.37% and 7.62% in the 30-day chart. Further, NewAmsterdam Pharma Company NV (NAMS) has a beta value of 0.28, and an average true range (ATR) of 1.57. Analysts have given the company’s stock an average 52-week price target of $45, forecast between a low of $41 and high of $48. Looking at the price targets, the low is -158.51% off current price level while to achieve the yearly target high, price needs to move -202.65%. Nonetheless, investors will most likely welcome a -183.73% jump to $45 which is the analysts’ median price.
If we refocus on NewAmsterdam Pharma Company NV (NASDAQ:NAMS), historical trading data shows that trading volumes averaged 1.55 over the past 10 days and 1.01 million over the past 3 months. The company’s latest data on shares outstanding shows there are 108.06 million shares.
The 48.10% of NewAmsterdam Pharma Company NV’s shares are in the hands of company insiders while institutional holders own 48.02% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 4.34 million on 2025-03-14, giving us a short ratio of 3.75. The data shows that as of 2025-03-14 short interest in NewAmsterdam Pharma Company NV (NAMS) stood at 594.9999799999999 of shares outstanding, with shares short rising to 2.91 million registered in 2025-02-14. Current price change has pushed the stock -38.29% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the NAMS stock continues to rise going into the next quarter.
